Chalazion

SightMD Welcomes Cynthia Zara, OD to its expert team in New York

Retrieved on: 
Monday, March 4, 2024
Diabetes, Ophthalmology, Food Network, Infection, Eye, Floater, Southern College of Optometry, Volunteering, State university system, School, Contact, Macular degeneration, Chalazion, OD, Patient, Glasses, Risk, Glaucoma, Food, Whaling

HAUPPAUGE, N.Y., March 4, 2024 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Cynthia Zara, OD to its expert team.

Key Points: 
  • SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Cynthia Zara, OD to its expert team.
  • HAUPPAUGE, N.Y., March 4, 2024 /PRNewswire-PRWeb/ -- SightMD, a leading multi-specialty ophthalmology platform in New York, welcomes Cynthia Zara, OD to its expert team.
  • Cynthia Zara, OD is a board-certified optometrist providing dilation exams, contact lenses and eyeglasses, dry eye treatments, and more.
  • When asked what she is looking forward to most about joining the SightMD Team, Dr Zara said "I am excited to be joining SightMD in Hamptons Bays and Southampton.

Exploring the Demodex Blepharitis Market: Clinical Viewpoints, Pipeline Evaluation, and Market Access Services | Disease Landscape Insights

Retrieved on: 
Monday, September 11, 2023
Infection, Pharma, Chalazion, Eyelash, Ocular rosacea, Signs and symptoms, Research, Inflammation, IgG4-related ophthalmic disease, Causes, Eyelid, DLI, Biological soil crust, Immune system, Growth, MITES, Ageing, Patient, Itch, Diagnosis, Stye, Meibomian gland dysfunction, Gland, FDA, R, Red, NIH, Skin, NME, Disease, Cosmetics, Agriculture, Medical device, Pharmaceutical industry, Demodex

Demodex Blepharitis is an inflammatory eye disorder caused by the uncontrollable growth of tiny mites known as Demodex on our eyelids.

Key Points: 
  • Demodex Blepharitis is an inflammatory eye disorder caused by the uncontrollable growth of tiny mites known as Demodex on our eyelids.
  • We at Disease Landscape Insights (DLI) aim to assist our clientele in understanding the characteristics of this disease and help them develop cutting edge treatment solutions.
  • Unlocking Insights into Demodex Blepharitis – From Research to Treatment Solutions, Dive Deeper into Managing this Eye Condition.
  • According to a data released by NIH, around 41% to 70% of the world's population are affected or highly prone to Demodex Blepharitis .

Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

Retrieved on: 
Thursday, April 20, 2023
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Hypersensitivity, Meibomian gland, Fetus, Safety, Cataract, Fungus, Dose, Development, Floater, Data analysis, Photophobia, Patient, Risk, Macular edema, Association for Research in Vision and Ophthalmology, Virus, NYSE, Chickenpox, Canker, ARVO, Pregnancy, Conjunctiva, Photopsia, Viral, HPA, Chemosis, Intraocular pressure, Administration, Uveitis, Bacteria, Chalazion, Hypothalamic–pituitary hormone, FDA, Lomb, Hyperglycemia, Perception, Efficacy, Eye, History, Sanfilippo, ARMOR, Triamcinolone, Cover My Eyes (Pain and Heaven), Intraocular lens, Glaucoma, Cornea, Research and development, Nursing, Telecanthus, Vaccinia, Asbell, Bausch & Lomb, Meibomian gland dysfunction, Visual acuity, Pharmaceutical industry, Wood drying, Vaccine, Telescopic sight, Dietary supplement, Ophthalmology, Kalahari Desert

“Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.

Key Points: 
  • “Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.
  • “Early Adoption of Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey.” Chang et al.
  • “Longitudinal Analysis of In Vitro Antibiotic Resistance Among Ocular Staphylococci Collected in the ARMOR study.” Asbell et al.
  • To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .

Bausch + Lomb Announces Scientific Data on XIPERE® (Triamcinolone Acetonide Injectable Suspension) to be Presented During the American Society of Retina Specialists Annual Scientific Meeting

Retrieved on: 
Wednesday, July 6, 2022
Suprachoroidal drug delivery, Canadian Securities Administrators, Patient, SCS, Canker, COVID-19, Hypersensitivity, Bausch & Lomb, Bacteria, Lens (anatomy), Floater, Uveitis, Degenerative disease, Pregnancy, Fetus, FDA, Dose, Triamcinolone, ASRS, Conjunctiva, Cataract, Nursing, Hypothalamic–pituitary hormone, Macular edema, NYSE, Cushing's syndrome, Cornea, Instagram, Twitter, Eye, LinkedIn, Administration, Duane syndrome, HPA, Virus, Chickenpox, News, Chalazion, Chemosis, U.S. Securities and Exchange Commission, History, Photophobia, Meibomian gland, Glaucoma, Fungus, Risk, Vaccinia, Cover My Eyes (Pain and Heaven), Visual acuity, Intraocular pressure, Facebook, Fear, Society, Photopsia, Hyperglycemia, Pharmaceutical industry, Silviculture, Vaccine, Telescopic sight

VAUGHAN, ON, July 6, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that five presentations highlighting data from the XIPERE® (triamcinolone acetonide injectable suspension) pivotal Phase 3 program will be presented at the American Society of Retina Specialists (ASRS) 40th annual scientific meeting, which will take place in New York from July 13-16, 2022. The presentations will include a new post-hoc analysis of the pivotal Phase 3 trial (PEACHTREE) evaluating outcomes following treatment with XIPERE® in patients with macular edema associated with chronic uveitis.

Key Points: 
  • "At this year's ASRS annual meeting, we look forward to sharing these data with retina specialists on XIPERE, which we launched commercially in March," said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb.
  • Suprachoroidal triamcinolone acetonide injectable suspension for macular edema associated with uveitis: Outcomes by anatomic subtypes in PEACHTREE.
  • Efficacy of suprachoroidal triamcinolone acetonide injectable suspension in the treatment of macular edema in patients with chronic uveitis.
  • XIPERE(triamcinolone acetonide injectable suspension) for suprachoroidal use is a corticosteroid indicated for the treatment of macular edema associated with uveitis.

NovaBay Pharmaceuticals’ Avenova® Warm Eye Compress for the Relief of Symptoms Associated with Dry Eye is Now Available on Amazon.com and Avenova.com

Retrieved on: 
Wednesday, March 31, 2021
Biotechnology, Pharmaceutical, Optical, Health, Infectious diseases, Cosmetics, Retail, Other Health, Ophthalmology, Organ systems, Anatomy, Eye, Meibomian gland, Stye, Blepharitis, Chalazion, Dry eye syndrome

(NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces the availability of its new Warm Eye Compress on Amazon.com and on Avenova.com .

Key Points: 
  • (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces the availability of its new Warm Eye Compress on Amazon.com and on Avenova.com .
  • This new, reusable heated eye compress is designed to relieve the symptoms associated with blepharitis, dry eye disease, meibomian gland disease, styes and chalazion, and is a companion product to Avenova, NovaBays premier antimicrobial lid and lash spray.
  • Avenova Warm Eye Compress helps to hydrate and lubricate eyes to efficiently expel bacteria and debris, making eyes feel refreshed and rejuvenated.
  • Currently in stock on both the Amazon and the Avenova websites, the Avenova Warm Eye Compress is available for $17.50 and shipping is free on Avenova.com.